Chemomab Therapeutics (CMMB) Earnings Date, Estimates & Call Transcripts $3.32 +0.04 (+1.22%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$3.25 -0.07 (-2.08%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Chemomab Therapeutics Earnings Summary Chemomab Therapeutics released Q2 2025 earnings on August 14, 2025, reporting an EPS of -$0.36, which beat analysts' consensus estimates of -$0.80 by $0.44. With a trailing EPS of -$2.36, Chemomab Therapeutics' earnings are expected to grow next year, from ($1.00) to ($0.70) per share. Upcoming Q3 Earnings DateNov. 13Before Market OpensEstimatedConsensus EPS (Aug. 14) -$0.80 Actual EPS (Aug. 14) -$0.36 Beat By $0.44 Q2 2025 Earnings ResourcesQ2 2025 Earnings Report Press Release (8-K)CMMB Upcoming EarningsChemomab Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled on Tuesday, November 11, 2025 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Powered by Get Chemomab Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chemomab Therapeutics and other key companies, straight to your inbox. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Estimated and Actual Earnings DataCMMB Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Chemomab Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.80-$0.80-$0.80Q2 20251-$0.80-$0.80-$0.80 Chemomab Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 11/13/2025(Estimated)--------8/14/2025Q2 2025-$0.80-$0.36+$0.44-$0.09--5/15/2025Q1 2025-$0.80-$0.56+$0.24-$0.14--8/21/2024Q2 2024-$0.80-$1.04 -$0.24-$0.26--5/9/2024Q1 2024-$0.80-$1.12 -$0.32-$0.28--3/7/2024Q4 2023-$1.60-$1.04+$0.56-$0.26--11/9/2023Q3 2023-$2.40-$1.36+$1.04-$0.34-- Chemomab Therapeutics Earnings - Frequently Asked Questions When is Chemomab Therapeutics' earnings date? Chemomab Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 13th, 2025 based off last year's report dates. Learn more on CMMB's earnings history. Did Chemomab Therapeutics beat their earnings estimates last quarter? In the previous quarter, Chemomab Therapeutics (NASDAQ:CMMB) reported ($0.36) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.80) by $0.44. Learn more on analysts' earnings estimate vs. CMMB's actual earnings. How much profit does Chemomab Therapeutics generate each year? Chemomab Therapeutics (NASDAQ:CMMB) has a recorded net income of -$13.94 million. CMMB has generated -$2.36 earnings per share over the last four quarters. What is Chemomab Therapeutics' EPS forecast for next year? Chemomab Therapeutics' earnings are expected to grow from ($1.00) per share to ($0.70) per share in the next year. More Earnings Resources from MarketBeat Related Companies ABVC BioPharma Earnings Gain Therapeutics Earnings Sutro Biopharma Earnings Artiva Biotherapeutics Earnings Precision BioSciences Earnings BeyondSpring Earnings Relmada Therapeutics Earnings Tvardi Therapeutics Earnings MiNK Therapeutics Earnings NRx Pharmaceuticals Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Goldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall This page (NASDAQ:CMMB) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging cryp...Weiss Ratings | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredBankrupt to billionaire after retirement?Expert Reveals: The #1 Retirement Play for 2025 "We're Entering the Greatest Energy Bull Market Since the I...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
